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INTRODUCTION 
 Anaemia during pregnancy is defined by World Health Organization 
as hemoglobin concentration of < 11gm/dl. It is most often caused by iron 
deficiency. It is one of the most serious global public health problem, affects 
52% of pregnant women in developing and 23% in developed countries. 
(Cochrane data review)1 
 
 In under developed countries, anaemia is a major contributory factor 
to maternal morbidity, mortality and higher perinatal mortality rate.  
 
Anaemia in pregnancy is associated with  
1. An increased risk of preterm delivery 
2. Low birth weight 
3. Maternal mortality 
 
 During pregnancy, anaemia is most often (about 80%) caused by iron 
deficiency and occasionally by more complex conditions involving deficient 
production or accelerated destruction of erythrocytes.   
 
Iron is an essential component of hemoglobin as it is the oxygen 
carrying pigment in blood. The pregnant women needs 1000mg of iron all 
through pregnancy i.e. 3.5mg / day to maintain iron balance. The demand 
during later half of pregnancy and for several weeks after delivery increases 
to about 6.7mg /day. 
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 Early pregnancy  - 2.5 mg / day 
 20-32 Weeks - 5.5 mg / day 
 32 weeks onwards  - 6-8 mg / day 
 
 Iron deficiency is the most frequent nutritional deficiency disorder in 
the world. Around 600-700 million people world wide have a marked iron 
deficiency anaemia. In India, despite the measures taken to control anaemia 
in pregnancy and lactation in the last two decades, the severity of nutritional 
anaemia contrinues to remain a public health issue of great magnitude (KN 
Aggarwal et al 2006). 2 
 
 Iron is an important constituent of Hemoglobin, myoglobin and some 
enzymes. It serves as a carrier of oxygen and electrons and acts as a catalyst 
for oxygenation and hydroxylation. It also has the ability to catch and  
release an electron (Fe++ / Fe+++ cycling). 
 
 The marked physiological adjustments occurring in pregnancy, are not 
sufficient to balance its very marked iron requirements. The reasons for the 
predominance of this etiological factor are 
 
1. The suboptimal Iron content of diet 
2. The insufficient iron stores in the majority of women during their 
reproductive years.  
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Iron deficiency anaemia exposes women to an increased risk of blood 
transfusion during the peripartum period because the parturient can no longer 
cope with physiologic blood losses of delivery, let alone those associated 
with hemorrhagic delivery. The risk is equally increased by conditions that 
incur chronic bleeding during gestation, such as placenta praevia. 
 
There are various treatment modalities for Iron deficiency anaemia 
during pregnancy. They are  
 
1. Various forms of Iron preparations (Oral tablets,  Parenteral Iron)  
2. Blood transfusion 
3. Erythropoietin 
 
 Long term oral treatment can produce side effects, especially digestive 
ones, which can lead to noncompliance. Parenteral administration by 
intramuscular injection is a painful alternative with a variable degree of 
efficacy. Among the iron preparations, iron sucrose iv preparation 
significantly increases the hematological indices with less side effects and 
allergic reactions.  
 
 Mostly anecdotal evidence suggests that I V and I M iron 
administration  is associated with allergic reactions. compared with I.M iron, 
IV. iron sucrose significantly increased hematological indices with less side 
effects.  (Cochrane Database syst Rev, 2006;3; CD004736)3 
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 Cochrane review conducted (in 2007),randomised controlled trials 
evaluating the effects of treatments for iron deficiency anaemia in 
pregnancy, and provide robust valid and useful evidence to inform clinical 
practice. The study concluded that blood transfusion carries the risk of 
transmitting parasitic or viral infections including HIV, hepatitis, and  chagas 
disease (trypanosomiasis), despite preventive blood screening. There is also 
the possibility of bovine spongiform encephalitis, and as yet unknown viral 
infections.  There is also risk of transfusion related acute lung injury  
(TRALI)4  
 
This was the study, conducted in Department of obstetrics and 
gynaecology Kilpauk Medical College, comparing the safety, efficacy and of 
2 different modalities of treatment, iv Iron sucrose and blood transfusion in 
the treatment of iron deficiency anaemia in pregnancy. 
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                          DESCRIPTION OF IRON SUCROSE  
Iron sucrose injection, is a brown, sterile, aqueous, complex of 
polynuclear iron (III)-hydroxide in sucrose for intravenous use. Iron sucrose 
injection has a molecular weight of approximately 34,000 – 60,000 daltons 
and a proposed structural formula: 
 
                 [Na2Fe5O8(OH) ·3(H2O)]n·m(C12H22O11) 
 
Where n  is the degree of iron polymerization and m is the number of 
sucrose molecules associated with the iron (III)-hydroxide. 
 
Each ml contains 20 mg elemental iron as iron sucrose in water for 
injection. Iron sucrose is available in 5 ml single dose vials (100 mg 
elemental iron per 5 mL) and 10 ml single dose vials (200 mg elemental iron 
per 10 ml). The drug product contains approximately 30% sucrose w/v (300 
mg/mL) and has a pH of 10.5-11.1. The product contains no preservatives. 
The osmolarity of the injection is 1,250 mOsmol/L. 
Therapeutic class: Hematinic 
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Clinical Pharmacology  
Pharmacodynamics& Pharmacokinetics: 
Following intravenous administration, iron sucrose is dissociated by 
the reticuloendothelial system into iron and sucrose.  In healthy adults 
treated with intravenous doses of Iron sucrose, its iron component exhibits 
first order kinetics with an elimination half-life of 6 hours, total clearance of 
1.2 L/h, non-steady state apparent volume of distribution of 10.0 L and 
steady state apparent volume of distribution of 7.9 L. Since iron 
disappearance from serum depends on the need for iron in the iron stores and 
iron utilizing tissues of the body, serum clearance of iron is expected to be 
more rapid in iron deficient patients treated with Iron sucrose as compared to 
healthy individuals.  
 
Distribution: 
 In healthy adults receiving intravenous iron sucrose, its sucrose 
component appears to distribute mainly in blood and to some extent in 
extravascular fluid. A study evaluating Iron sucrose containing 100 mg of 
iron labeled with 52Fe/59Fe in patients with iron deficiency shows that a 
significant amount of the administered iron distributes in the liver, spleen 
and bone marrow and that the bone marrow is an iron trapping compartment 
and not a reversible volume of distribution. 
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Metabolism and Elimination:  
Following intravenous administration of Iron sucrose, iron sucrose is 
dissociated into iron and sucrose by the reticuloendothelial system. The 
sucrose component is eliminated mainly by urinary excretion. Some iron 
also is eliminated in the urine.  
 
Drug-drug Interactions:  
Drug-drug interactions involving Iron sucrose have not been studied. 
However, Iron Sucrose may be expected to reduce the absorption of 
concomitantly administered oral iron preparations. 
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AIM OF THE STUDY 
 
1. To compare the efficacy of intravenous iron sucrose with blood 
transfusion in the treatment of iron deficiency anaemia. 
 
2. To compare the safety of intravenous iron sucrose with blood 
transfusion in the treatment of iron deficiency anaemia 
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REVIEW OF LITERATURE 
 Iron sucrose that releases iron to the endogenous iron – binding 
proteins with a half life of about 6 hours is not only effective but carry a 
minimal risk of allergic accident and overload, especially after a 
comprehensive pretreatment work-up. Postmarketing experience in 25 
countries indicates that iron sucrose complex therapy is a valid first- line 
option for the safe and rapid reversal of iron – deficiency anaemia 
(Breymann, 2005).5 
 
 Iron sucrose has been effectively used in pregnancy with highest 
safety and tolerability among the iron preparations. Good tolerance to iron 
sucrose is partly due to the low allergenic effect of the sucrose complex, 
partly due to slow release of elementary iron from the complex. 
Accumulation of iron sucrose in parenchyma of organs is low compared with 
iron – dextran or iron – gluconate, while incorporation into the bone marrow 
for erythropoiesis is considerably faster. By using parenteral iron sucrose in 
cases of severe iron deficiency, anaemia during pregnancy is treated 
efficiently and safely according to results and the rate of blood transfusion 
could be reduced considerably to below 1% of patients per year (perwunyk 
et al, 2002).6 
 
Iron sucrose fits in the criteria for an ideal parenteral iron therapy as 
defined by Geissser et al in 1992. 
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A prospective, open controlled study was undertaken to evaluate the 
safety and efficacy of intravenous iron sucrose complex (ISC) as compared 
with oral ferrous sulfate in the treatment of iron deficiency anaemia during 
pregnancy (al Moment et al, 1996).7 In this study pregnant women with iron 
deficiency anaemia were sequentially selected from the antenatal clinic and 
assigned either to ISC (study group) or to ferrous sulfate (control group).   
 
Each study patient was given the total calculated amount of ISC (Hb 
deficit (g/l) x body weight (kg) x 0.3) in divided dose )200 mg elemental 
iron in 100 ml normal saline intravenously over 1 hour daily,  followed by 
10mg /kg to replenish iron stores. Each patient of the control group was 
given ferrous sulfate 30mg (60 mg elemental iron) orally three times a day. 
All patients were monitored for adverse effects, clinical and laboratory 
response. Results: There were 52 patient and 59 control. ISC group  achieved 
a significantly higher Hb level (128.5+/-6.6g/L vs. 111.4 +/- 12.4 g/l in the 
control group, P< or = 0.001).in a shorter period (6.9 +/- 1.8 weeks vs. 
14.9+/- 3.1 weeks in the control group , P<or = 0.001). ISC complex group 
showed no major side effects while 4 (6%) of the control group, could not 
tolerate ferrous sulfate, 18(30%) complained of disturbing gastrointestinal 
symptoms and 18 (30%) had poor compliance. The authors concluded that 
ISC was safe and effective in the treatment of iron deficiency anaemia 
during pregnancy.  
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Similarly iron  sucrose therapy in pregnancy was compared with oral 
iron therapy in a randomized open-label study (AI RA et al, 2005).8 In this 
study 90 women with hemoglobin levels between 8 and 10.5g/dL and ferritin 
values less than 13 mcg /L received either oral iron polymaltose complex 
(300mg elemental iron per day) or intravenous iron sucrose. The iron sucrose 
dose was calculated from the following formula: weight before pregnancy 
(kg) x(110 g/L- actual hemoglobin [g/L] x 0.2+500 mg. Treatment efficacy 
was assessed by measuring hemoglobin and ferritin on the 14th and 28th 
days and at delivery, and the hemoglobin on the first postpartum day. 
Adverse drug reactions, fetal weight, hospitalization time, and blood 
transfusions were also recorded. Hemoglobin values varied significantly 
with time between groups (interaction effect, P<.001).  
 
The change in hemoglobin from baseline was significantly higher in 
the intravenous group than  the oral group at each measurement’ the changes 
with respect to subsequent hemoglobin significantly higher in the 
intravenous group than the oral group at each measurement; the change  with 
respect to subsequent hemoglobin were significantly higher on the 14th 
(P=.004) and 28th (P=.031) days. Ferritin values were higher in patients 
receiving intravenous iron throughout pregnancy. No serious adverse drug 
reaction were observed. Fetal weight and hospitalization time similar in the 2 
groups. Blood transfusion was required for only one patient in the oral 
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group. Thus, intravenous iron treated iron – deficiency anaemia of pregnancy 
and restored iron stores faster and more effectively than oral iron, with no  
serious adverse reactions. 
 
Intravenous iron sucrose therapy was compared with intramuscular 
iron sorbitol in prospective comparative study in 60 pregnant women with 
IDA with the gestational age of 12-34 weeks (Wali et al, 2002).9 Patients 
were divided into  three groups A, B and C. Group A(n=15) received 
intravenous iron sucrose in a dose calculated using formula: weight before 
pregnancy (kg) x (110 g/L – actual) hemoglobin [g/L]) x 0.24 +500 mg. 
Group B(n=20) also received intravenous iron sucrose but dose was 
calculated as weight before pregnancy (kg) x (110 g/L- actual hemoglobin 
[g/L[ ) x 0.24 + 200 mg. Group C(n=25) received intra muscular iron 
sorbitol. After 3 weeks of therapy, Hb increased by 2.8 g/dl (group A) and 
1.9g/dl in group B. Prior to delivery (ave:6.6 weeks ) there was a total rise in 
Hb of 3.8g/dl (group A) and 2.4 g/dl  (group B). In group C, the Hemoglobin 
was assessed only prior to delivery and a rise of 1.4 g/dl was observed. 
Target hemoglobin levels  i.e 11 g/dl was achieved by 80% in Group A, 70% 
in Group B and 28% in Group C by the time of delivery. In conclusion, 
intravenous iron therapy was found to be safe, convenient and  more 
effective than intramuscular iron therapy in treatment of iron deficiency 
anaemia during pregnancy.  
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 Hoigne et al (1998)10 compared safety of iron sucrose with iron 
dextran. They investigated whether there were differences in the frequency 
of ADRs (adverse drug reactions) to parenteral iron preparations. They 
evaluated different datasets.  
 
1. In 206 patients, 4 probably allergic reactions to i.m. iron dextran were 
found, one with acute severe dyspnea, cyanosis and flush, 3 with slight 
generalized, probably allergic reactions. Data from the USA on i.v. 
iron dextran did not show marked differences in the frequency of 
ADRs as compared with their data with i.m. administration. 
2. A group of 400 otherwise healthy patients of the obstetric department 
of Zurich University Hospital were treated with i.v. iron sucrose for 
anaemia due to iron loss during pregnancy or following childbirth. 
Seven generalized skin reactions, 4 in the form of flush and 3 of 
common exanthema, occurred  
3. In a retrospective study, not a single life threatening reaction was 
observed during around 8100patient–years with approximately 
160,000 ampoules of iron sucrose (With 100 mg elementary iron) 
,only 5-7 situations of rapidly reversible blood pressure fall occurred, 
10 with flush, and one each with urticaria and vomiting / diarrhea.   
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 Postpartum blood loss is also associated with iron deficiency anaemia. 
Severe anaemia, unless corrected may prove to be fatal for the mother. Dede 
et al (2005)11 conducted a comparative study in 75 puerperal women with 
iron deficiency anaemia (Hb 9g/dL). Patients were divided into two groups: 
IV group given iron sucrose IV and oral group given 60 mg elemental iron 
three times a day. Evaluation was done after 7 days and after 28 days of 
starting the therapy. Hb, serum ferritin, serum iron, haematocrit, MCV and 
total serum iron binding capacity were measured. The authors concluded  
that compared with oral iron therapy, intravenous iron significantly increased 
serum ferritim levels within a short period of time with fewer incidences of 
adverse effects than oral iron in postpartum women with iron deficiency 
anaemia.  
 
 Francoise Bayoumeu et al (2005)12 in their study to compare oral iron 
versus iron sucrose concluded that apart from being more effective, Iron 
sucrose  achieves the target levels in a short time. This paves the way for 
other potential indications, such as anaemia discovered late in the pregnancy 
or in patients who have low iron reserves and present a risk of hemorrhage 
during peripartum, such as in multiple pregnancy or over distention of the 
uterus, in hope of avoiding a transfusion. This possibility should be explored.  
 
Al Moment et al13 conducted a prospective open – label controlled 
trial in 111 pregnant women with iron deficiency anaemia (Hb :<9 gm/dl) 
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and divided into 2 groups. Intravenous group (N.55) and intramuscular 
group. Intravenous iron sucrose was administered as an infusion of single 
100 mg dose in normal saline every 1 to 3 days.  
 
Controls received I.M iron dextran (100mg on alternate days) till the 
calculated dose was reached. Intravenous iron therapy resulted in higher 
levels of Hb, with the time to achieve maximum Hb in shorter period 
compared with controls. No serious adverse effects were noted in iron 
sucrose group whereas 6% of patients could not tolerate I.M iron dextran, 
who excluded from the study. 30% of patients in the control group had 
disturbing GI symptoms and 32%  were non complaint. 
 
 Wali A, MushtaqA, Nilofer.9 (Journal Pakistan med. Assoc. 2002 sep 
52(9) : 392-5) conducted a prospective  comparative study, total number of 
60 pregnant women with gestational age of 12-34 wks with iron deficiency 
were included and divided into 2 groups.  Group A (N: 30) received intra 
venous iron sucrose according to recommended dose containing 500mg of 
iron sucrose for storage Group B (n=30) received intramuscular iron dextran. 
Mean Hb in group A was 8.0 +/- 1.1gm/dl and in group B was 8.8 +/-
0.9gm/dl. In group A and B, initial Hb was assessed and 3 weeks after 
therapy which showed an average rise of 2.8gm/dl in group A and 1.4 gm/dl 
group B. Target Hb level of 11gm/dl was achieved in 80% of  group A, 28% 
of group B patients. In group A one patients had moderate abdominal pain, 2 
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had weakness and shivering, 3 had phlebitis but none of the patients 
discontinued the therapy due to adverse effects.In group B majority, 
complained of pain at the injection site. In which 5 patients dropped out from 
study due to intolerance. They concluded that I.V iron therapy is safe, 
convenient and more effective then I.M Iron therapy, hence I.V iron therapy 
can replace blood transfusion in antenatal period.     
 
Breyman et al14 conducted a prospective randomised open study 
evaluated the efficacy and safety of intravenous iron sucrose with or with out 
recombinant human erythropoietin in correcting iron deficiency anaemia (Hb 
<10 gm/dl) in pregnant women ie. Gestational age (> 21 weeks) .20 patients 
received recombinant human erythropoietin 300 IU/Kg and iron sucrose 
200mg I.V and 20 patients received I.V iron sucrose 200 mg alone twice 
weekly for 4 weeks till a target Hb of 11 gm/dl was achieved. There was 
immediate reticulocyte response and progressive rise in haematocrit in both 
groups . Higher rise in reticulocyte count and rise in haematocirt was 
observed in the group that received combination therapy. None required 
blood transfusion. No serious adverse effects were reported. They concluded 
that I.V iron sucrose alone should be considered first in iron deficiency 
anaemia during pregnancy, recombinant human erythropoietin may be 
considered in severe anaemia requiring rapid correction, not responding to 
I.V iron sucrose. 
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Scoff B. Silvestein and George Reodgers.15 
The increased availability of parenteral iron preparation should 
decrease the need to use red cell transfusion in patients with iron deficiency 
anaemia.  
 
             Sal-Momen Ak, el al-Mechari A; al – Nuaime L et al in                    
199616 conducted a study comparing I.V iron sucrose and oral ferrous 
sulphate, they observed that iron sucrose complex group achieved 
significantly higher Hb level (128.5+/- 6.6mg/dl Vs 111.4 +/- 12.4g/I) in 
control group. P<or =0.001. Iron sucrose complex showed no major side 
effects, but 6% of control group could not tolerate ferrous sulphate . 30% 
had poor compliance in the control group. They concluded that iron sucrose 
complex is safe and effective in the treatment of iron deficiency anaemia 
during pregnancy.  
 
 Bayoumeu F, subrian – Buisset E, Baka NE et al (2002)17 American 
journal of Obst and Gynaecology also observed  the effectiveness, safety and 
tolerability of I.V iron sucrose compared to oral iron for treatment of iron 
deficiency anaemia in pregnant women.  
 
 Gravier A, Descargues G, Marpeace L et al (1999)18 conducted a study 
on how to avoid postpartum blood transfusions in Iron deficiency anaemia 
patients, by treating with I.V Iron sucrose. They concluded that I.V Iron 
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sucrose is effective in preventing unnecessary blood transfusion in 
postpartum patients. 
 
  Scott B, Silvestein and Geroge M et al (2004),15 they have observed 
that increase in Hb first noted after 1 week of irons sucrose administration 
and serious anaphylactic hypersensitivity 0.002% in I.V iron sucrose group 
compared 0.6-0.7% in I.M iron dextran group.  
 
Wested S, Beake B, Smedvig E et al19 studied the effect of intravenous 
iron sucrose compared with oral ferrous sulphate, they concluded that 
women who received. I.V iron sucrose replenished their iron stores more 
rapidly and had more symptomatic relief compared to oral iron.  
 
Iron sucrose is safe to administer in pregnant diabetics who need IV 
iron supplementation. (Pharmacotherapy. 2007 Mar; 27(3) : 343-50).20 
 
 Iron sucrose is safe in patients with cardiac problems when they need 
IV iron supplement (J Am Coll Nutr 1995;14:71-79).21 
 
Intravenous iron, treated iron – deficiency anaemia of pregnancy and 
restored iron stores faster and more effectively than oral iron, with no serious 
adverse reactions. (ACOG Vol. 106, No. 6, December 2005) 22 
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Intravenous iron sucrose increase the Hb level more rapidly than oral 
ferrous sulphate in women with postpartum iron deficiency anaemia. It also 
appears to replenish the iron stores more rapidly.  (BJOG 2006; N Bhandal, 
R Russell).23 
 
A prospective, open, controlled study , conducted by EJOG concluded 
that Iron sucrose complex is safe and effective in the treatment of iron 
deficiency anaemia during pregnancy.  (European Journal of Obstetrics & 
Gynecology and Reproductive Biology 69 (1996) 121-124).24 
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IRON METABOLISM 
 Most of the iron within the body is found in hemoglobin within 
erythrocytes (about 1800mg of iron). Iron is stored in macrophages (and to a 
lesser extent in hepatocytes), which represents the storage pool of iron (about 
1600 mg of iron.). Small amounts of iron are found in myoglobin and in 
plasma (bound to transferrin).Iron is conserved within the body.  The typical 
adult human body contains about 3000 – 4000 mg of iron. Only about 1 mg 
of iron is lost from the body per day (through blood loss or sloughed 
mucosal epithelial cells) and must be replaced through the diet. The majority 
of iron required by the body is acquired by recycling iron from senescent red 
cells.   
 
 Iron  is important in human body because of its occurrence in many 
hemetopoietins such as hemoglobin, myoglobin & cytochromes. Digested in 
diet as heme or non heme iron. (Harper’s illustrated Biochemisty – 26th 
Ediciton). 
 
Iron  
 Most of the iron in the diet is in the ferric (fe3+)  form, whereas it is the 
ferrous (Fe2+) form that is absorbed. Fe3+ will be converted into Fe2+ by 
Fe3+ reductase in the brush border of enterocytes (Willima F. Ganong 21st 
Edition).  
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Sources and contents of Iron  
Milk   : Human Milk 0.5 mg 
(Litre)  Cow’s Milk 0.02 – 0.3 mg 
 
Foods  : a) Pulses (9-11 mg) 
(80-100 mg)      cereals (4-11 mg) 
   b) Meat, Fish (10-25 mg) 
   c) Ripe Banana (0.9 mg) 
    Mango (1.3mg) 
    Melon (7.5 mg) 
Iron absorption  
 Normally greater proportion of dietary heme iron than non  heme iron 
is absorbed reflecting the greater importance of heme as source of iron. (B 
Jorn Ramussen et al 1974). 
 
 Almost all iron absorption occurs in the duodenum. Iron absorption is 
facilitated by reducing substances like ascorbic acid, Amino acids.  
 
Sugars especially fructose increase the absorption and  may contribute 
to dietary hemosiderin of  Bantus, who consume a diet high in sugar.  
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 Iron absorption is inhibited by alkalies, phosphates, phytates (Maize, 
Wheat), also by mucosal block i.e., gut has a mechanism to prevent entry of 
excess iron in the body.  
 
 Daily iron requirement for menstruating adult female and pregnancy 
(last 2 trimesters ) is 1-2mg and 3-5 mg respectively.  
 
 Good mixed diet provides 10to 15 mg of iron/day. Normal  absorption 
of 10% or so is enough to replace the loss but not able to replace the extra 
demands of body growth. (Harper’s illustrated Biochemistry- 26th Edi) 
 
Iron absorption in gastrointestinal tract   
 Dietary iron is obtained either from inorganic sources or animal 
sources (in heme from breakdown of hemoglobin or myoglobin). Dietary 
iron enters intestinal cells via specific transporters. The iron is then used by 
the cell (incorporated into enzymes), stored as ferritin (excreted in the feces 
when the intestinal epithelial cells sloughs) or is transferred to the plasma. 
Transfer of iron from enterocytes to the transpor4t protein, apotansferrin, 
occurs through specific iron channels, called ferroportins, and is facilitated 
by a protein (with ferroxidase activity) called hephaestin. When 
apotransferrin binds iron, it is called transferrin. Hephaestin contains copper, 
so copper deficiency will decrease iron absorption (as the iron absorbed from 
the diet cannot be transferred to plasma). Hepcidin,a main iron regulating 
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protein, decreases ferroportin and thus decreases  iron absorption. Normally 
transferrin is about 35% saturated with iron.  
 
 
 
 
  
 
 
 
 
 
Heme is transported into the enterocyte by seperate heme transporter 
(HT), and heme oxidase releases Fe2+ from the heme. Some of the Fe2+ is 
converted to Fe3+ and bound to ferritin. The rest binds to basolateral Fe2+ 
transporter ferroportin (FP), and bound to transferrin and stored in the body 
as ferritin and hemosiderin.  
 
 Ferritin containing cells are exfoliated from the mucosal surface at the 
end of 2-3 days life span. (Conrad and Barton 1981) 
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Transferrin does not cross that placenta but gives up its iron in 
chorionic villus, Iron is transferred across the placenta against steep 
concentration gradient, so it is enzyme dependent. (Waller Stein 1973) 
 
The plasma tranferrin is less than that expected from TIBC. (Vander 
Heul et al 1972) 
 
Erythorid progenitors obtain iron for hemoglobin synthesis from 
plasma transferrin or from recycling of senescent erythrocytes by 
macrophages in bone marrow, spleen and liver. Iron that is in excess of that 
required for hemoglobin production is stored in macrophages as ferritin, 
which is oxidized to hemosiderin. These stores can be released from 
macrophages in times of need (increased erythropoietin).  
 
Iron transfer/recycling 
Iron is not free in the circulation but exists as transferrin (bound to 
apotransferrin). Most of the iron used for red blood cell hemoglobin 
production is obtained from hemoglobin breakdown of senescent RBCs 
(called recycling). When red blood cells reach the end of their lifespan 
(senescent), they are phagocytized by macrophages (in the spleen, liver, bone 
marrow). Hydrolytic enzymes in macrophages degrade the ingested RBCs 
and release hemoglobin. Proteolytic digestion of hemoglobin liberates heme 
and globins. Globins are broken down to amino acids which can be used for 
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protein production. The iron is released from heme, leaving a porphyrin ring 
which is converted to bilirubin. Once iron is released from the heme, it is 
utilized by the cell (iron is an essential component of many enzymes), 
exported (via ferroportin), or stored as ferritin (like enterocytes). In 
macrophages, ceruloplasmin (which like hephaestin in intestinal cells also 
requires copper) is a ferroxidase and facilitate the transfer of macrophage 
iron to transferrin.  
 
Iron uptake by eythroid progenitors 
Transferrin-bound iron (from absorption of dietary iron in the intestine 
or released by macrophages) binds to transferrin receptors, which are highly 
expressed on the surface of red cell precursors, and is taken up into the cells 
where it is used to form hemoglobin. Erythroid progenitors cluster around 
macrophages in the bone marrow and spleen because they are obtaining their 
iron (required for hemoglobin synthesis) from these iron-storing cells, as 
well as from circulating transferrin. 
 
First step is condensation of glycine with succinate, this is iron 
dependent. Protoporphyrin IX synthesis is inhibited by iron deficiency. 
(Ganong 21st Edition) 
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ERYTHROPOIESIS 
Erythropoiesis is the development of mature red blood cells 
(erythrocytes). Like all blood cells, erythroid cells begin as pluripotential 
stem cells. The first cell that is recognizable as specifically leading down the 
red cell pathway is the proerythroblast. As development progresses, the 
nucleus becomes somewhat smaller and the cytoplasm becomes more 
basophilic, due to the presence of ribosomes. In this stage the cell is called 
a basophilic erythroblast . The cell will continue to become smaller 
throughout development. As the cell begins to produce hemoglobin, the 
cytoplasm attracts both basic and eosin stains, and is called 
a polychromatophilic erythroblast . The cytoplasm eventually becomes more 
eosinophilic, and the cell is called a northochromatic erythroblast . This 
orthochromatic erythroblast will then extrude its nucleus and enter the 
circulation as a reticulocyte . Reticulocytes are so named because these cells 
contain reticular networks of polyribosomes. As reticulocytes loose their 
polyribosomes, they become mature red blood cells. 
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RBC production is a complex process starting from stem cells all the way to 
mature RBCs, a process that takes about 25 days. 
• RBC is released into circulation from bone marrow, but before release of 
RBC, it requires incorporation of iron into it.  
• Proerythroblast (day 20 of RBC formation) is the stage where 
incorporation of iron takes place.  
• Iron incorporation happens within 24 to 72 hrs window period just 
before the young RBC is ejected into the circulation.  
• Proerythroblasts turns into a mature RBC within 5 days.   
• In severe anaemia, the hypoxic state induces high amount of 
erythropoietin (EPO) secretion. In this high EPO state, the erythropoiesis 
up to day 20 is accelerated. IV iron in such high EPO state can stimulate 
erythropoiesis by 5 times normal rates.  
• Administration of iron through intravenous route makes available high 
quantity of elemental iron for incorporation at the proerythroblast stage 
and hence iron sucrose administration can provide quick Hb rise within 5 
to 7 days.  
 33
IRON DEFICIENCY ANAEMIA 
Iron deficiency anaemia is the most common nutritional deficiency in 
pregnancy followed by folate deficiency anaemia. Out of 150 million 
deliveries occurring annually in the world, approximately 6,00,000 women 
die from the complications of pregnancy. Anaemia is responsible for 40%-
60% of maternal deaths in non-industrialized countries. Anaemic mother is 
more likely to succumb to the ill effects of hemorrhage, be susceptible to 
infection and suffer from congestive cardiac failure. (Progress in obstet and 
gynaecology, STUDD volume 15).25 
 
 WHO criteria for diagnosis of anaemia in pregnancy is Hb content of 
<11 gm/dl (7.45 mmol/l) and haematocrit of less than33%. CDC (Centers for 
Disease control, USA)26 proposes a cut off point of 10.5 gm/dl during the 
second trimester. (Progress in obstet and gynaecology, STUDD volume 15). 
 
ICMR categories of anaemia.27  
Category   Severity  Hb level (gm/dl) 
1.   Mild   10.0 – 10.9 
2.   Moderate  7.0 – 10.0 
3.   Severe  <7.0 
4.   Very severe  <4.0 
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Iron Deficiency Anaemia;  
Prevalence of anaemia in pregnancy 
 Anaemia affects about 18% of women during pregnancy in 
industrialised countries while in non-industrialised countries, prevalence 
varies between 35-75% ,average being 56%. Incidence of anaemia in India 
ranges between 20 and 30% in the middle income group and much higher in 
low income group (60%) and 70% in rural women. 
(Progress in OBG, STUDD volume 15) 
 
Iron Requirements in Pregnancy  
Basal iron     - 280mg, 
Expansion of red cell mass - 570mg 
Transfer to the fetus  - 200-350mg 
Placenta    - 50-150mg 
Blood loss at delivery  - 100-250mg 
 
After deducting iron conserved by amenorrhoea (240-480 mg), an 
additional 500-600 mg of iron is required in pregnancy or 4-6 mg/day of 
absorbed  iron i.e. 2.5 mg/day in early pregnancy, 5.5 mg/day from weeks 
20-32 and 6-8 mg/day from weeks 32 onwards. 
 
As absorption is less than 10%, atleast 40-60 mg of iron should be 
available in the diet. 
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Causes of high prevalence of Iron deficiency anaemia; 
1. Increased iron requirement 
2. Dietary habits 
 
Consumption of low bio availability diet, also higher in both Hindu 
vegetarian and Muslim (Halal Meat eaters), this could be due to loss of 
significant amounts of heme blood from the Halal meat where the animal is 
slaughtered by cutting its carotid artery and bled to death. 
 
(Sharma and Soni 1999). 
 
1. Defective iron absorption due to intestinal infection like hook worm, 
schistosomiasis, chronic malaria. 
2. Menorrhagia / Bleeding from the gut due to haemorrhoids. 
 
 
States of Iron deficiency anaemia; 
Stage I : Negative iron balance 
 Demands for iron exceed the body’s ability to absorb iron from diet. 
 Normal Hb / haematocrit level  
 Normal RBC indices  
 Serum Ferritin <20ng/ml 
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Stage II: Iron deficient Erythropoiesis  
 When stores become depleted, serum iron begins to fall, total iron 
binding capacity rises gradually and once the transferrin falls to 15 to 20%, 
Hb synthesis becomes impaired. 
 
State III : Iron deficiency anaemia 
 Peripheral picture reveals microcytic and hypochromic cells appearing 
as vacuolated red blood cells with reticulocytes in circulation. Gradually Hb 
and haematocrit begins to fall. Transferrin saturation <15%. 
 
Clinical Features  
Patient may be asymptomatic especially in mild and moderate 
anaemia. Patient may complain of weakness, exhaustion, indigestion, loss of 
appetite, palpitation, dyspnoea, giddiness and edema. Congestive cardiac 
failure can occur in severe cases. 
 
Signs: 
 There may be no signs especially in mild anaemia. There may be 
pallor, glossitis and stomatitis. Patient may have edema due to 
hypoproteinemia. Soft systolic murmur can be heard in mitral area due to 
hyperdynamic circulation. There can be fine crepitations at bases of lungs 
due to congestion.  
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Effects of anaemia on pregnancy 
Maternal effects 
 Mild anaemia may not have any effect on pregnancy and labour 
except that the mother who has low iron stores, may become moderate to 
severely anemic in subsequent pregnancies. Moderate anaemia may cause 
increased incidence of preterm labour (28.2%), pre-eclampsia (31.2%) and 
sepsis. 
 
 During labour there is an increased incidence of postpartum 
hemorrhage and congestive cardiac failure. 
 
 During puerperium, there is an increased chances of puerperal sepsis,  
sub involution, failing lactation and venous thrombosis. 
 
Fetal effects 
 Irrespective of the maternal iron stores, fetus tends to obtain iron from 
maternal transferrin. But gradually the fetal iron stores becomes depleted. So 
babies born to anaemic mother should be started on oral iron in the infancy 
itself. 
 
 Iron deficiency anaemia is a significant risk factor for prematurity and 
low birthweight infants, if it is present in first trimester. In 2nd and 3rd 
trimester, it had little effect on these fetal outcomes. (School et al). 
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 Lozoff et al observed a significant effect of anaemia on the affective 
behavior of an anaemic child. 
 
Diagnosis 
 Although the assessment of iron status in human population is 
advanced compared with other nutrients, there is still a large uncertainty 
about absolute diagnosis during pregnancy. (Am J Clin Nutr. 1994: 59 
(Suppl) 5025 – 10s).28 
 
Parameters Normal 
Negative 
iron 
balance 
Iron deficient 
erythropoiesis 
Iron 
deficiency 
anaemia 
Marrow iron stores  1 – 3 + 0 – 1 + 0 0 
Serum ferritin (ng/ml) 50-200 <20 <15 <15 
TIBC (mg/dl) 300-360 >360 >380 >400 
Serum iron (mg/dl) 50-150 Normal <50 <30 
Saturation (%) 30-50 Normal <20 <10 
Marrow sideroblasts 
(%) 
40-60 Normal <10 <10 
RBC protoporphyrin 
(mg/dl) 
30-50 Normal >100 >200 
RBC morphology Normal Normal Normal Microcytic 
hypochromic
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Red cell indices 
 Among the Red cell indices, MCV is the first to get reduced and is the 
most sensitive indicator of iron deficiency anaemia. MCHC is reduced in 
more severe cases of iron depletion. 
 
    Normal Iron deficiency anaemia 
 MCV (fl)  75.96  reduced 
 MCHC (g/dl) 32.35  reduced 
 
Prophylactic Supplementation 
 WHO recommendation based on the prevalence of anaemia 
< 40% : 60mg elemental iron and 0.4mg of folic acid. 
> 40% : supplemented for another 3 months postpartum. 
 
National nutritional anaemia control programme guidelines. 
 100mg of elemental iron and 0.5mg of folic acid for minimum of 100 
days, starting in the 2nd trimester and continued 3 months postpartum.  
 
Treatment of iron deficiency anaemia 
 Iron deficiency anaemia is the main cause of anaemia during 
pregnancy. Iron should be the mainstay of therapy oral, parentral or through 
transfusion. 
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 Breymann 2005 explained that the efficacy of oral or intramuscular 
iron is limited in many patients, due to dose dependent side effects, lack of 
compliance and insufficient duodenal iron absorption, and correction of 
hematological and iron status parameters are still lacking. 
 
 Breymann 2005 also stated that transfusion has many problems 
including transmission of viruses and bacteria, RBC quality can be 
compromised during storage and the possibility of transmitting prions is an 
increasing worry. 
 
 Breymann 2005 maintained that following I.V iron sucrose 
administration, it is not necessary to survey the patient (or) monitor their 
blood pressure, the patient can leave with 100% compliance.  
 
 The increased availability of multiple parenteral iron preparations 
should decrease the need to use red cell transfusions in patients with Iron 
deficiency anaemia. (Am. J. Hemetol 76 : 76 -78, 2004)29 
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MATERIALS AND METHODS 
 
Study Setting : Kilpauk Medical College Hospital 
   Department of Obstetrics and Gynaecology 
Study Design : Prospective Randomized Control Study 
Study Period  : November 2009 to October 2010 
Sample Size   : Determined by Statistical analysis. Statistical analysis 
done was done by using chi square test & student ‘t’ test & ‘p’ value in 
appropriate places.About 100patients were randomized for either Iron 
sucrose or blood transfusion. A ‘p’ value less than 0.05 is taken to denote 
significant relationship. 
 
Inclusion criteria for the patients 
Following criterias were utilized in selecting patients for this study   
 Age 18-45 yrs  
 Singleton pregnancy between 28 to 34 wks  
 Hb – 7- 8 gm/dl 
 
Exclusion Criteria   
1. Underlying disease such as hypertension, gestational diabetes, heart 
disease, peptic ulcer.  
2. H/o allergy to iron containing medication.  
3. H/o other allergic conditions or asthma.  
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4. Thalassemia.  
5. H/o Bleeding tendency.  
 
After confirming iron deficiency anaemia using  
 Hemoglobin  
 Haematocrit 
 MCV 
 Peripheral smear   
 
Antenatal  patients with iron deficiency anaemia who fulfilled the 
above said criteria were randomly allocated into 2 groups. Group I and 
Group II. each Group contains 50 antenatal patients.  
 
After obtaining an informed consent, a detailed history taking, a 
complete general examination and detailed obstetric examination were done.  
 
Method of the Study  
Calculation of iron requirement  
 Iron requirement is calculated using the following formula  
2.4 x (target Hb – patient Hb ) x Pre pregnancy weight (kg) +500 (Storage 
iron ) = mg of elemental iron  
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 Group I patients were given intravenous iron sucrose complex, 100 
mg of elemental iron diluted in 100 ml of 0.9% normal saline was infused 
over 15min, on alternate days until the required dose was infused. Test dose 
was not given. 
 
 Group II patients were given one unit of packed cell transfusion, Hb 
was reassessed after 48 hours, further transfusions were given  until the 
required Hb was achieved.  
 
Observation  
During therapy the following parameters were monitored  
1. Vitals (Pulse, BP, Temperature ) 
2. Adverse effects like nausea / vomiting / abdominal pain, chills etc. 
3. Anaphylactic reactions.  
4. Urine output  
 
Patients were advised to attend our OPD 2 weeks after therapy and the 
following parameters were assessed.  
1. Symptomatic improvement  
2. Hb 
3. Haematocrit  
4. MCV 
Follow up 
 GA at delivery: preterm / term delivery  
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RESULTS OF THE STUDY 
Table 1 
AGE DISTRIBUTION 
 
Age in Years 
Group I Group II Total 
% No. of 
Cases 
Percentage No. of 
Cases 
Percent
age 
<20 10 20 8 16 18% 
21-25 28 56 21 42 49% 
26-30 9 18 14 28 23% 
>30 yrs 3 6 7 14 10 % 
Total 50 100% 50 100 100% 
 P = 0.271            Not significant  
INFERENCE 
 There is no significant change in the age distribution between the two 
age Group. Among 100 women studied, 18%,were less than 20 years, 49% 
of patients belongs to the age Group 21-25 yrs,  23% belong to age Group 
26-30 yrs, and  10% belong to age >30 yrs. 
The mean age was 23.48 & 25.08 in Group A and Group B 
respectively. 
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FIGURE 1 
AGE DISTRIBUTION 
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Table 2 
BOOKING STATUS 
 
 
Booking status  
Group I Group II 
Total % No. of 
Cases 
Percentage No. of 
Cases 
Percentage 
Booked  18 36 26 52 44% 
Unbooked  32 64 24 48 56% 
Total  100 100 100 100 100 
 P = 0.107       Not Significant 
 
INFERENCE  
The booking  status of both group I and group II were same . 
Among the 50 patients in Group I ,36% were booked, 64% were 
unbooked. In Group II, 52% were booked and 48% were unbooked. There 
was no significant change in both group. 
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FIGURE 2 
BOOKING STATUS 
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Table 3  
OBSTETRIC CODE 
 
 
GRAVIDA  
Group I Group II  
Total 
% 
No. of 
Cases 
Percentage No. of 
Cases 
Percentage 
1 24 48 24 48 48% 
2 20 40 15 30 35% 
3 4 8 6 12 10% 
4 2 4 5 10 7% 
Total  100 100 100 100 100 
 P = 0.494       Not Significant 
 
INFERENCE  
48% of patients in Group I and 48% of patients in Group II, were 
primigravida,   while only 4% in Group I and 7% Group II were gravid 4. 
Both primi and multipara were equally distributed in both the Groups.    
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FIGURE 3  
OBSTETRIC SCORE  
 
 
 50
Table 4 
SOCIO ECONOMIC STATUS 
 
 
SOCIO 
ECONOMIC 
STATUS 
Group I Group II  
Total 
% 
No. of 
Cases 
Percentage No. of 
Cases 
Percentage 
Class I 0 0 0 0 0 
Class II 0 0 0 0 0 
Class III 2 4 5 10 7 
Class IV 23 46 23 46 46 
Class V 25 50 22 44 47 
Total  50 100 50 100 100 
 P = 0.452       Not Significant 
 
INFERENCE  
47% of women belonged to class V socio economic status, 46% 
belonged to class IV socioeconomic class.  
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FIGURE 4 
SOCIO ECONOMIC STATUS 
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Table 5 
Change in Hemoglobin  
 
Hemoglobin
(gm/dl)  
Group I Group II  
P 
Value  
N  Mean  S.D S.E.M N Mean S.D S.E.M 
Pre 
Treatment 
50 7.498 0.332 0.0469 50 7.55 .374 .0530 0.431 
Post 
Treatment   
50 10.943 0.337 0.04767 50 11.09 .501 .07093 0.089 
Change in 
Hb 
50 3.44 .420 .0595 50 3.51 .429 .0607 0.417 
                                                                                                   Not Significant  
 
INFERENCE  
 Mean Hb in Group I and Group II was 7.498 gm/dl and 7.55 
respectively. Post therapy Hb after 2 weeks showed a mean Hb value of 
10.943 gm/dl and 11.09gm/dl respectively (P-0.089) which was statistically 
not significant. 
 
 The average rise of Hb was 3.44 gm/dl and 3.51 gm/dl respectively in 
Group I and Group II (P-0.417) which was statistically not significant.  
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FIGURE   5 
CHANGE IN HEMOGLOBIN  
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Table 6 
CHANGE IN HAEMATOCRIT 
 
 
Haematocrit 
(Percentage) 
Group I Group II  
P Value N  Mean  S.D S.E.M N  Mean S.D S.E.M
Pre 
Treatment 
50 28.4 1.39 .196 50 30 1.5 .213 .212 
Post 
Treatment   
50 33.99 1.56 .221 50 38 1.25 .1767 .496 
Change in 
Haematocrit 
50 5.51 1.77 .250 50 8 1.23 .17509 .072 
                                                                                                   Not Significant  
 
INFERENCE  
 Among 100 patients studied, Haematocrit in Group I and Group II was 
28.4% and 30.0% respectively. Post therapy Haematocrit after 2 weeks 
showed a mean Haematocrit value of 33.99% and 38.0% respectively                  
P value is (.496) which was statistically not significant. The average gain of 
Haematocrit was 5.5% and 8.0% in Group I and Group II respectively, 
which was statistically not significant.       
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FIGURE 6 
CHANGE IN HAEMATOCRIT 
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Table 7 
CHANGE IN MCV 
 
 
MCV(fl)  
Group I Group II  
P 
Value 
N  Mean  S.D S.E.M N Mean S.D S.E.M 
Pre 
Treatment 
50 69.19 3.707 .524 50 69.03 2.58 .365 0.803
Post 
Treatment   
50 86.69 1.868 .264 50 86.01 1.90 .268 .074 
Change in 
MCV 
50 17.496 3.616 .511 50 17.09 2.96 .418 0.547
P= .574                                                                                      Not Significant  
 
INFERENCE  
Among 100 patients studied, Mean MCV in Group I and Group II was 
69.19fl and 69.03fl respectively. Post therapy assessment after 2 weeks in 
Group I and Group II Showed a Mean MCV value of 86.69fl and 86.01fl 
respectively (P=.574) which was not statistically significant. The average 
gain in MCV was 17.49 fl and 17.09 fl in Group I and Group II respectively. 
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FIGURE 7 
CHANGE IN MCV 
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Table 8 
SYMPTOMS  
Symptoms  Group I  Group II  
No. of .Cases  No. of .Cases  
Easy fatiguability and  
pallor  
27 22 
Breathlessness and 
pallor  
5 4 
Pallor of Skin and 
Mucus  Memb 
13 19 
Easy fatiguability pallor 
& breathlessness  
5 5 
Total  50 50 
 
SYMPTOMATIC IMPROVEMENT   
 
Symptomatic 
Improvement   
Group I (n=50) Group II (n=50) 
No. of 
Cases 
Percen
tage 
No. of 
Cases 
Percentage 
Easy fatiguability and  
pallor  
27/27 100 22 100 
Breathlessness and pallor 5/5 100 4 100 
Pallor of Skin and Mucus  
Memb 
13/13 100 19 100 
Easy fatiguability pallor 
& breathlessness  
5/5 100 5 100 
P  value=0. 0627        Not Significant  
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INFERENCE  
In Group I , among 27 patients with easy fatiguability and pallor and 
5patients with breathlessness (Grade I) and pallor and 13 patients with only 
pallor and 5 patients with all the three findings, all (100%) experienced 
improvement of symptoms after  intravenous Iron sucrose therapy.  
 
And in Group II also, among 22 patients with easy fatiguability and 
pallor , 4 patients with Breathlessness and pallor, 19 patients with only 
pallor, 5 patients with all the three findings, all (100%)  experienced 
improvement of symptoms after blood transfusion. Thus, there was no 
statistical significance.  
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Table 9 
ADVERSE EFFECTS 
 
No. of 
Cases 
Patients with  
Adverse effects 
Patients without  
Adverse effects 
Group I 50 0 50 
Group II  50 22 28 
 
Chi - squre  = 28.205  P = 0.000  SIGNIFICANT 
Table 9 
ADVERSE EFFECTS 
 
ADVERSE 
EFFECTS 
Group I Group II  
Total 
% 
No. of 
Cases 
Percent
age 
No. of 
Cases 
Percentage 
Chills and rigor   0 0 12 24% 12% 
Nausea and  
Vomiting  
0 0 0 0 0 
Itching  0 0 8 16 8 
Join Pain  0 0 0 0 0 
Headache  0 0 2 4 2 
Anaphylactic reaction  0 0 0 0 0 
Thrombophlebitis  0 0 0 0 0 
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FIGURE  9 
ADVERSE EFFECTS 
 
 
 
 
 
 
 
 
 
 
 
INFERENCE  
 Among 50 patients studied in Group I, adverse effects were almost nil. 
But in Group II more adverse effects like headache 2/50 (4%) chills and 
rigor  12/50  (24%), itching 8/50 (16%) were found. But there was no 
anaphylactic reactions noted in both the groups P value is 0.000. 
Adverse reactions were statistically significant between the two groups 
studied.   
 
 
 62
Table 10 
GESTATIONAL AGE AT DELIVERY 
 
 
GA at delivery  
Group I Group II 
 
No. of .Cases  
 
Percentage 
 
No. of .Cases  
 
Percentage  
Pre term  5 10 13 26 
Term  45 90 37 74 
Total  50 100 50 100 
 
P= 0.01866                             Significant  
 
Among 100 patients studied, 10% (5 patients) in Iron sucrose group 
(Group I), 26% (13 Patients) in blood transfusion group (Group II) delivered 
preterm. P Value is 0.01866 which was statistically Significant. 
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FIGURE 10 
GESTATIONAL AGE AT DELIVERY 
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 DISCUSSION 
In our study 100 antenatal patients with iron deficiency anaemia were 
selected according to the inclusion and exclusion criteria stated in 
methodology. They were divided into 2 groups (50 patients each) 
 
In Group I, 50 Antenatal patients were given injection Iron sucrose 
100 mg IV Infusion over 15-20 minutes on alternate days, until the 
calculated does was infused  
 
In Group II, 50 Antenatal patients were given blood transfusion 
(Packed cell) once in 2 days until the required hemoglobin was achieved. 
  
 During treatment adverse reactions were noted.  
 
All the patients were advised to attend our OP department,2 weeks after 
treatment and the following parameters were assessed.  
 
1. Symptomatic improvement  
2. Hemoglobin  
3. Haematocrit  
4. MCV  
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• In our study, 18% (18/100) of the patients were < 20 years of age. 49% 
(49-100) of the patients 20% (20/100) of the patients were in the age 
group of 26-30 years and 13% (13/100) of the patients were >30 yrs. In 
our study, 56% of the patients were unbooked and 44% were booked. 
Booked and unbooked cases were equally distributed in 2 groups.  
 
• In our study, 47% of women belonged to class V socio economic status 
and 46% belonged to Class IV socio economic status. Majority of the 
women with iron deficiency anaemia were in low socio economic group.  
 
• In our study, 35% of patients were primipara and 52% were multipara.  
 
• In our study, all patients (100%) experienced symptomatic improvement 
in both Iron sucrose group and blood transfusion group. There was no 
statistical difference between the two groups studied.  
 
CHANGES IN HEMOGLOBIN.  
In our study, hemoglobin level was measured before treatment and 
again after 2 weeks, post treatment assessment was done using sahli’s 
hemoglobinometer at Kilpauk Medical College Hospital Laboratory.  
 
Mean Hb in Group I and Group II was 7.49 gm/dl and 7.55 gm/dl 
respectively. Post treatment Hb after 2 weeks showed an mean Hb of 10.943 
gm/dl and 11.096gm/dl respectively. An average rise in Hb was 3.44 gm/dl 
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and 3.51 gm/dl (P- 0.417) which was statistically not significant and the 
target Hb was achieved in 100% of women in both the groups studied.  
 
Our study, similar to the study by Francoise bayoumeu et al (2005), 
Iron sucrose, apart from being more effective, Iron sucrose achieves the 
target levels in a short time. This paves the way for the other potential 
indications, such as anaemia discovered late in pregnancy or in patient who 
have low iron stores and present a risk of haemorrhage during postpartum, 
such as in multiple pregnancy or over distention of the uterus, in hope of 
avoiding a transfusion.  
 
The average Hb rise in both the groups were same, hence iron sucrose 
is as effective as blood transfusion, in achieving the target hemoglobin in a 
shorter time.   
 
The following studies in support of our study  
S.No Name of the Study Rise in Hb(gm/dl) 
Our Study 
(Iron Sucrose)
1 Wali et al 2002 3.8 gm/dl 3.4 gm/dl 
2. EJOG 199623 3.2 gm/dl 3.4 gm/dl 
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CHANGE IN HAEMATOCRIT  
In our study, the mean haematocrit in Group I and Group II was 
28.4%  and 30%  respectively. Post treatment haematocrit assessment after 2 
weeks showed an mean haematocrit value of 33.99% and 38.0% 
respectively. The P value is 0.1767 which was not statistically significant.  
 
The average rise of haematocrit was 5.51% and 8.0% in Iron sucrose 
group and blood transfusion group, which was also not statistically 
significant.   
 
The following studies in support of our study: 
S.No Name of the Study Haematocrit 
Our Study 
(Iron Sucrose)
1 Breymann et al 2005 ↑ ↑ 
2. Dede et al (2005)11 ↑ ↑ 
 
 
CHANGE IN MCV  
 In our study, Mean MCV in Group I and Group II were 69.19 fl and 
69.03 fl respectively. Post treatment MCV assessment, after 2 weeks showed 
mean MCV value of 86.69 fl and 86.01 fl respectively with P= .574,which 
was statistically not significant. 
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The average rise in MCV was 15.886 fl and 17.09 fl in Group I and 
Group II  in the P value of 0.476 which was also not significant.  
 
A study by Mrs. Khurshid Shabir Raja et al30, journal of Pakistan 
Medical association, Vol. 28 showed mean MCV before treatment was 65 fl, 
mean MCV 3 weeks after treatment showed 75 fl and the mean rise in MCV 
was 10 fl with P value <0.5 which was statistically significant. This study 
was comparable with our study.  
 
Adverse Reactions: 
 In our study, there was no adverse reactions in women treated with 
Iron sucrose for the treatment of Iron deficiency anaemia. On the otherhand, 
In Group II, patients treated with blood transfusion, there were more side 
effects, headache 2/50 (4%),  chills and rigor 12/50 (24%), and Itching 8/50 
(16%) of the patients. 
 
 Our study, similar to a observation, published in Journal of 
Transfusion Alternatives in transfusion medicine 9 (Supp 1.2) 13-18, which 
stated that blood transfusion for Iron deficiency anaemia is the most 
expensive and most hazardous form of therapy. Transfusion hazards are 
indeed numerous and well documented. The awareness of these risks of 
blood transfusion, together with the limited availability of blood due to 
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increasing shortages, should encourage physicians to seek alternative 
therapies to correct anaemia.31 
 
 
The following studies in support of our study: 
 
S.No Name of the Study Adverse Reactions 
Our Study 
(Iron Sucrose)
1 Al Ra 2005 No  No 
2. Al Moment et al No No 
3. Hoigne et al No No 
 
 
Gestational Age at delivery: 
 In our study, 10% of patients in Group I and 26% of patients in Group 
II delivered preterm. Though the incidence of preterm delivery is high in 
anaemia complicating pregnancy, the incidence of preterm delivery was high 
in the patients treated with blood transfusion, according to our study.  
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SUMMARY 
In our study, 100 antenatal patients with iron deficiency anaemia 
attended to Kilpauk Medical College Hospital OP department between 
November 2009 to October 2010, selected according to the inclusion and 
exclusion criteria, already stated in methodology, were taken for this 
randomized controlled study.  They were allocated into 2 groups of each 
with 50 antenatal patients.  
 
GROUP I  – Treated with Iron sucrose  
GROUP II – Treated with Blood Transfusion  
 
The results of the study are tabulated ,analysed and summarized as 
follows:- 
1. Majority of the patients, around 49% belonged to the age group 
between 21-25 years in both Group I and Group II.  
2. Booked and unbooked patients were equally distributed in both 
groups.  
3. Majority (93%) of the women belonged to class IV and class V socio 
economic status in both Group I and Group II .  
4. Both primi and multipara were equally distributed in both Group, 48% 
patients were primi and 52% were multipara. 
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5. All the patients (100%) in Group I and Group II had symptoms of easy 
fatiguability, breathlessness (Grade I), and pallor of skin and mucus 
membranes on examination.  
6. Symptomatic improvement observed in all cases (100%) in both 
intravenous Iron sucrose group and blood transfusion group.  
7. Mean rise in hemoglobin was 3.44 gm/dl in Intravenous iron sucrose 
group (Group I), 3.51 gm/dl in blood transfusion group (Group II). 
The gain in hemoglobin in both the groups were same.  
8. Target Hb was achieved in 100% of patients in both group I and             
Group II.  
9. Mean rise in haematocrit value was 5.5% in iron sucrose group  
(Group I) and 8.0% in blood transfusion group (Group II). The rise in 
haematocrit in both Group I, Group II were almost same, which was 
not statistically significant.  
10. Mean rise in MCV was 17.49 fl and 17.09 fl in Group I and Group II 
respectively. The rise in MCV in both Group I and Group II were 
same.  
11. The adverse effects were not at all observed in iron sucrose group 
(Group I) compared to 22% of the patients in blood transfusion group 
(Group II),  P-0.000 value is which was statistically significant.  
12. The incidence of preterm delivery was high in Blood transfusion  
Group II (26%) than in Group I (10%). 
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CONCLUSION 
 
 Intravenous iron sucrose is as effective as blood transfusion, in 
improving hemoglobin, haematocrit values in the treatment of iron 
deficiency anemic during pregnancy.  
 It is safe and well tolerated when compared to blood transfusion  
 The adverse effects in intravenous iron sucrose treatment are not seen 
when compared to blood transfusion. 
 The incidence of preterm delivery was high in patients treated with 
blood transfusion.  
 Thus, it was concluded that, intra venous iron sucrose in the treatment 
of Iron deficiency anaemia in pregnancy is as effective as blood 
transfusion and it is safe, without adverse effects when compared to 
blood transfusion  
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PROFORMA 
 
Name     : 
Age     :  
Obstetric Score   : 
Booking Status   : 
Socio Economic Status  : 
Chief Complaints    : 
 H/o easy fatiguability 
 H/o  breathlessness 
 H/o  palpitation 
 H/o passing worms  
 H/o  bleeding pr /hemetemesis/ hematuria  
 H/o bleeding diathesis  
Past History  
Any H/o Dm/HT/Bronchial Asthma/Cardia disease / thyroid disease /  
  
General Examination: 
 Anaemia   Dyspnoea    jaundice 
 Pedal edema   JVP 
 PR:  BP:  RR: 
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Systemic examination 
 Repiratory system  
 Cardio vascular system 
 Central nerovous System: 
 
Obstetric Examination: 
 P/A: uterus- fundal height  
  FH- 
INVESTIGATIONS:  
1. Complete blood  count   
Hb 
Haematocrit  
Total Count  
Differential count  
ESR  
Platelets 
2. Peripheral smear  
3. Urine- albumin  
Sugar  
Deposits  
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4. Blood Sugar  
5.  Blood Grouping & typing  
6. VDRL 
7. NVP 
8. HBs Ag 
9. BT 
10. CT 
11. Sr. Protein 
12. MCV 
13. Motion - Ova 
   - Cyst 
14. Urine – Culture – Sensitivity. 
15.  Obstetric Ultrasound 
During Treatment  
The following are monitored  
1. PR  
2. BP 
3. Chills and rigor  
4. Nausea and vomiting  
5. Itching  
6. Joint pain  
7. Head ache,  
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8. Anaphylactic reaction  
9. Urine output                                                                                                      
 
Post treatment assessment after 2 weeks  
1.  Hb% 
2. Haematocrit  
3. MCV                                                         
4.  Symptomatic Improvement.  
 
Follow Up  
GA at delivery :  Term / pre term  
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KEY TO MASTER CHART 
 
S. No.    - Serial Number 
B    - Booked 
UB    - Un Booked 
GA    - Gestational age. 
SES    - Socio Economic Status.  
Hb    - Hemoglobin in gm / dl 
Pre    - Prior to Iron Sucrose / Blood transfusion  
Post     - Post Treatment  
MCV    - Mean corpuscular Volume 
OBST .Score   - obstetric Score  
Symp. Improvement  - Symptomatic Improvement.  
Easy fatig    - Easy Fatiguability  
G    - Gravida 
P    - Para 
L    - Live Children 
A    - Abortion.    
GA at delivery   - Gestational age at delivery  
T    -  Term delivery  
PT    -  Preterm delivery   
Gm/dl    - gram per deciliter  
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LIST OF ABBREVIATIONS USED 
 
Hb  - Hemoglobin  
gm/dl  - gram / decilitre  
mg   - milligram  
Fe++  - ferrous Ion  
Fe+++  - Ferric Ion 
ISC  - Iron Sucrose complex 
MCV  - Mean corpuscular volume  
RBC  - red blood cell  
I.V  - intravenous  
H/o  - History of  
Wks  - weeks  
FH  - fetal heart  
Bp   - Blood pressure  
PR  - Pulse rate  
GA  - Gestational Age  
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